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a cBACKGROUND Potent cholesteryl ester transfer protein (CETP) inhibitors have been shown to substantially increase
high-density lipoprotein cholesterol (HDL-C) and apolipoprotein A-I levels as monotherapy and combined with statins.
However, data on the effects of this class of drugs on macrophage cholesterol efﬂux capacity (CEC), a functional assay
that characterizes a key step in the process of reverse cholesterol transport, are limited.
OBJECTIVES This study assessed the impact of evacetrapib, statins, or combination therapy on CEC.
METHODS We analyzed samples from 377 subjects with elevated low-density lipoprotein cholesterol (LDL-C) or low
HDL-C levels who were enrolled in a phase 2 trial of evacetrapib. Percent changes from baseline in CEC (total, non–
ABCA1-, and ABCA1-speciﬁc) and HDL subpopulations were evaluated after 12 weeks of treatment with placebo, statin
monotherapy, evacetrapib monotherapy, or evacetrapib combined with statins. Pre–beta-1 HDL levels were quantiﬁed by
immunoﬁxation and nondenaturing 2-dimensional gel electrophoresis (2DGE).
RESULTS Relative to placebo, evacetrapib monotherapy increased dose-dependent total and non–ABCA1-speciﬁc CEC
up to 34% and 47%, respectively. Evacetrapib monotherapy also increased ABCA1-speciﬁc CEC up to 26%. Relative to
statin monotherapy, evacetrapib with statins also increased total, non–ABCA1-, and ABCA1-speciﬁc CEC by 21%, 27%,
and 15%, respectively. In contrast, rosuvastatin and simvastatin signiﬁcantly reduced total and ABCA1-speciﬁc CEC,
whereas atorvastatin had no signiﬁcant effect. Consistent with ABCA1-speciﬁc CEC, evacetrapib monotherapy and
evacetrapib combined with statins signiﬁcantly increased pre–beta-1 HDL levels as measured by either method.
CONCLUSIONS Evacetrapib, as monotherapy and combinedwith statins, not only increased total CEC, but also increased
ABCA1-speciﬁc CEC and pre–beta-1 HDL. The mechanisms by which potent CETP inhibition increases ABCA1-speciﬁc CEC
and pre–beta-1 HDL require further study. (A Study of LY2484595 in Patients With High LDL-C or Low HDL-C;
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2202P otent cholesteryl ester transfer pro-tein (CETP) inhibitors substantiallyincrease high-density lipoprotein
cholesterol (HDL-C) levels as monotherapy
and in combination with statins (1–4). Levels
of HDL-C are known to inversely associate
with the prevalence and incidence of athero-
sclerotic cardiovascular disease (ASCVD) in
epidemiological studies, independently of
all other major risk factors (5). Randomized
controlled trials with HDL-C–raising medica-
tions and genetic mechanisms that raise
HDL-C levels have suggested that HDL-C
may not be causally associated with ASCVD
(6–9). However, Mendelian randomization
studies have linked common CETP variants
associated with low CETP activity, high
HDL-C, and reduced LDL-C to a 4% lower
risk of myocardial infarction (7).SEE PAGE 2211Cholesterol efﬂux from peripheral tissues is a key
function of HDL particles, and the ﬁrst step of reverse
cholesterol transport to the liver for biliary secretion
(10). Recent studies have shown that cholesterol
efﬂux capacity (CEC) is inversely associated with
prevalent ASCVD (11,12) and incident cardiovascular
events in a population-based cohort without cardio-
vascular disease at baseline (11,13). These associations
were independent of HDL-C and traditional cardio-
vascular risk factors, which suggested that the HDL-C
level is only a modest biomarker of HDL function, and
that CEC may be more closely correlated with car-
diovascular outcomes.
Lipid-poor pre–beta-1 HDL particles are believed to
be one of the primary acceptors of cholesterol
efﬂuxed from macrophages via the adenosine
triphosphate–binding cassette transporter A1 (ABCA1)
(14). ABCA1 is primarily localized in the plasma
membrane of cells, and ABCA1-mediated cholesterol
efﬂux to lipid-poor pre–beta-1 particles is essential for
HDL formation. Thus, ABCA1-speciﬁc cholesterol
efﬂux is generally correlated with lipid-poor pre–
beta-1 HDL, but is not correlated with large HDL
particles (15). However, although ABCA1 is a major
mediator of macrophage cholesterol efﬂux, HDL also
promotes macrophage cholesterol efﬂux via ABCG1is, Esperion, and MedImmune, but requires companies to donate
eives neither income nor a tax deduction. Dr. Rader serves on the
Novartis, Pﬁzer, and Sanoﬁ. All other authors have reported that t
to disclose.
received June 10, 2015; revised manuscript received August 26,and probably other pathways as well (16). ABCG1 is
also expressed in vascular endothelium, where it
mediates cellular sterol efﬂux to large HDL particles
(17). Thus, ABCA1 and ABCG1 have complementary
functions in mediating cholesterol efﬂux to HDL, and
their association with cardiovascular disease is not
clear (18). However, data on the regeneration of pre–
beta-1 HDL and the role of ABCA1-speciﬁc cholesterol
efﬂux following pharmacological CETP inhibition are
limited.
In this study, we assessed the changes from base-
line in CEC and HDL subclasses after 12 weeks of
treatment with evacetrapib monotherapy, statin
monotherapy, or evacetrapib in combination with
statins in dyslipidemic patients. The relationship
among changes in CEC and CETP mass or activity,
HDL subclass, HDL-C, and apolipoprotein A-I (apoA-I)
concentrations was also assessed. We demonstrate
that evacetrapib, at different doses as monotherapy
and at the 100 mg/day dose in combination with
statins, increased pre–beta-1, alpha-1, and alpha-2
HDL levels, with corresponding increases in both
non–ABCA1- and ABCA1-speciﬁc CEC.
METHODS
STUDY DESIGN. This was a multicenter, randomized,
double-blind, parallel, placebo-controlled trial con-
ducted among 398 patients with elevated low-density
lipoprotein cholesterol (LDL-C) or low HDL-C. The
details of the study design, conducted from April 2010
to January 2011 in the United States and Europe, have
been previously reported (4). The study was con-
ducted in accordance with the Declaration of Helsinki
and the Guidelines for Good Clinical Practice. All pa-
tients provided informed consent, and the local
institutional review committees approved the study.
This study evaluated the effects of 12 weeks of
treatment with evacetrapib as monotherapy and in
combination with statins. For the monotherapy
evaluation, patients were randomly assigned to
receive either placebo or evacetrapib at daily doses of
30, 100, or 500 mg. For the combination treatment
groups, patients were randomly assigned to receive
either placebo or evacetrapib 100 mg, in combination
with atorvastatin 20 mg, rosuvastatin 10 mg, or sim-
vastatin 40 mg. Changes from baseline in CEC,all honoraria or consulting fees directly to charity so
advisory boards of Aegerion, Alnylam, Eli Lilly and
hey have no relationships relevant to the contents of
2015, accepted September 5, 2015.
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2203pre–beta-1 HDL, and HDL subclasses were evaluated
after 12 weeks from available samples in 377 subjects.
STUDY PARTICIPANTS. Patient inclusion and
exclusion criteria have been previously described
(4). In brief, this study included patients who were
at least 18 years old and were eligible on the basis
of meeting low HDL-C or high LDL-C criteria, in the
presence of triglyceride levels <400 mg/dl. Patients
who met the low HDL-C criteria had an HDL-C level
of <45 mg/dl for men or 50 mg/dl for women, with
an LDL-C level that met the current National
Cholesterol Education Program Adult Treatment
Panel III goal. Patients who met the high LDL-C
criteria had LDL-C levels between 100 and 190 mg/dl
in the presence of 0 or 1 risk factors; LDL-C levels
between 100 and 160 mg/dl with at least 2 risk factors
and a 10-year coronary risk of <10%; or LDL-C levels
between 100 and 130 mg/dl with at least 2 risk factors
and a 10-year risk of 10% to 20%, in the presence
of any level of HDL-C. Patients were excluded
if they had any clinical manifestation of atheroscle-
rotic disease, hypertension (systolic blood pressure
>140 mm Hg or diastolic blood pressure >90 mm Hg),
documented hyperaldosteronism, uncontrolled dia-
betes (hemoglobin A1C $8%), or signiﬁcant liver,
kidney, cardiac, or neuromuscular disease.
STUDY PROCEDURES. Fasting blood samples were
obtained at baseline and week 12 for the measure-
ment of CEC, pre–beta-1 HDL, and HDL subclasses.
CEC (total, ABCA1-speciﬁc, and non–ABCA1-speciﬁc)
was quantiﬁed in blood samples by depleting patient
serum of apoB particles using polyethylene glycol
precipitation (11). The intra-assay and interassay co-
efﬁcients of variation were 8% and 10% for total
efﬂux, and 9% and 15% for ABCA1-speciﬁc efﬂux,
respectively (11). Non–ABCA1-speciﬁc efﬂux was
calculated as the difference between total and ABCA1-
speciﬁc efﬂux. Pre–beta-1 HDL levels were measured
in plasma using an immunoﬁxation method validated
by the isotope dilution technique by O’Connor et al.
(19). Assays were run in duplicate with intra-assay
and interassay coefﬁcients of variation of 6% and
7%, respectively (20). HDL subclasses (alpha- and
pre–alpha-1, -2, -3, and -4, and pre–beta-1) were also
quantitatively determined by nondenaturing 2D
gel electrophoresis (2DGE) (21,22); 2DGE samples
were only available for 199 subjects at baseline and
week 12. The coefﬁcient of variation was <15% for all
particles assessed using the nondenaturing 2DGE
method.
STATISTICAL ANALYSIS. Demographic, baseline, and
on-treatment data were summarized using fre-
quencies for categorical variables and mean  SD ormedian and interquartile range for continuous vari-
ables. For each of the cholesterol efﬂux and HDL
subclass measures, patients in the intention-to-treat
population with both baseline and post-baseline
values were analyzed using analysis of variance.
The response variable of the model used for all ana-
lyses was percent change from baseline to week 12 or
early discontinuation in the analyzed measure; the
explanatory variables were baseline measurement
and treatment. Results were reported as least-square
means and 95% conﬁdence intervals by treatment.
For the evaluation of evacetrapib monotherapy,
comparisons were made between individual evace-
trapib dosages and placebo, as well as between
pooled evacetrapib monotherapy and placebo. The
statin combination evaluation reﬂected comparisons
of statins in combination with evacetrapib 100 mg
with respective individual statins. Pooled statins in
combination with evacetrapib 100 mg were also
compared with pooled statins. In addition, individual
statins and pooled statins were compared with pla-
cebo. Correlations among the investigated measures
were assessed by Pearson’s correlation coefﬁcients
for their baseline levels, their levels at week 12 or
early discontinuation, and their changes from base-
line to week 12 or early discontinuation. The p values
for the comparisons were presented, and statistical
signiﬁcance was indicated at p < 0.05 and p < 0.001.
All analyses were conducted using SAS version 9.2
(SAS Institute, Inc., Cary, North Carolina).
RESULTS
SUBJECT BASELINE CHARACTERISTICS. The overall
disposition of patients participating in this study has
been previously reported (4). A total of 398 patients
were randomized to receive placebo (n ¼ 38), statin
monotherapy (n ¼ 123), evacetrapib monotherapy
(n ¼ 121), or evacetrapib with statin combination
therapy (n ¼ 116). Baseline characteristics were
similar across all treatment groups. Baseline CEC and
levels of HDL subpopulations are presented in Online
Tables 1 and 2.
CHANGES IN CHOLESTEROL EFFLUX CAPACITY.
Percentage changes from baseline to week 12 in total,
ABCA1-speciﬁc, and non–ABCA1-speciﬁc CEC are
shown in the Central Illustration and Online Tables 3
and 4 according to treatment. There was
no signiﬁcant change from baseline in the placebo
group. Compared with placebo, evacetrapib mono-
therapy signiﬁcantly increased total efﬂux capacity in
a dose-dependent manner, ranging from an 18%
increase at the 30-mg dose to a 34% increase at
the 500-mg dose. These changes were paralleled by
CENTRAL ILLUSTRATION Evacetrapib Enhances Total, Non–ABCA1-, and ABCA1-Speciﬁc Cholesterol Efﬂux Capacity,
Both in Monotherapy and in Combination With a Statin
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(A) Total, (B) non–ABCA1-, and (C) ABCA1-speciﬁc cholesterol efﬂux capacity. *p < 0.05; **p < 0.001 versus placebo; #p < 0.05; ##p< 0.001
versus statin counterpart. Atorva ¼ atorvastatin; Rosuva ¼ rosuvastatin; Simva ¼ simvastatin.
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2205dose-dependent increases in non–ABCA1-speciﬁc
efﬂux, which increased by up to 47% at the 500-mg
dose. Moreover, evacetrapib monotherapy also
signiﬁcantly increased ABCA1-speciﬁc efﬂux at the
100- and 500-mg doses (17% overall and up to 26%
across the 3 doses), but not in a dose-dependent
fashion.
Compared with placebo, statin monotherapy
(averaged across the 3 statins) decreased total, non–
ABCA1-speciﬁc, and ABCA1-speciﬁc cholesterol efﬂux
by 10%, 4%, and 17%, respectively. However, the 3
statins differed in their effects. Atorvastatin had no
statistically signiﬁcant effect on any of the efﬂux
measures, whereas rosuvastatin and simvastatin both
signiﬁcantly reduced total efﬂux (13% and 10%,
respectively) and ABCA1-speciﬁc efﬂux (20%
and 19%, respectively).
When evacetrapib 100 mg was combined with
statin therapy, efﬂux capacity signiﬁcantly increased,
but this effect was blunted compared with evace-
trapib monotherapy. In a pooled analysis across the 3
statins, evacetrapib combined with statins increased
total efﬂux by 21% (vs. statin monotherapy) compared
with an increase of 31% (vs. placebo) with the same
dose of evacetrapib as monotherapy. This same
pattern was seen for non–ABCA1-speciﬁc and ABCA1-
speciﬁc efﬂux (increases of 27% and 15% for evace-
trapib with statins vs. 33% and 26% for evacetrapib
100 mg monotherapy, respectively). When combined
with atorvastatin, evacetrapib had no signiﬁcant ef-
fect on ABCA1-speciﬁc efﬂux.
PRE–BETA-1 HIGH-DENSITY LIPOPROTEIN. Percent
changes from baseline to week 12 in pre–beta-1 HDL
levels are shown in Figure 1 by treatment. Consistent
with the efﬂux data, pooled evacetrapib mono-
therapy signiﬁcantly increased pre–beta-1 HDL levels
measured by either immunoﬁxation (Figure 1A) or
2DGE (Figure 1B) compared with placebo. In contrast,
pooled statin monotherapy decreased pre–beta-1
HDL levels (p < 0.05 for 2DGE). Consistent with the
efﬂux data, pooled evacetrapib 100 mg combined
with statins signiﬁcantly increased pre–beta-1 HDL
levels by either method (p < 0.05 by immunoﬁxation
and p < 0.001 by 2DGE compared with statin mon-
otherapy), but the magnitude of the effect was
smaller than that observed with evacetrapib 100 mg
as monotherapy.
APOLIPOPROTEIN A-I–CONTAINING HDL SUB-
POPULATIONS. Percent changes from baseline to
week 12 in HDL subpopulations are shown in Figure 2
and Online Tables 5 and 6. Evacetrapib monotherapy
signiﬁcantly increased alpha-1 by 208%, pre–alpha-1
by 174%, and pre–beta-1 HDL by 45% compared withplacebo, and these increases were dose-dependent.
Evacetrapib monotherapy also increased alpha-2
by 14% and decreased pre–alpha-3 by 24%, but
these effects were not dose-dependent. Pooled
statin monotherapy had no signiﬁcant effect on HDL
subpopulations, except for a 26% increase in pre–
alpha-2 HDL levels compared with placebo. Pooled
evacetrapib combined with statins also signiﬁcantly
increased alpha-1 by 164%, pre–alpha-1 by 106%, and
pre–beta-2 by 40% compared with pooled statin
monotherapy, and these increases were evident for
all statins. As seen for evacetrapib monotherapy, an
increase in alpha-2 and decrease in pre–alpha-3 were
also observed with evacetrapib combined with statins
versus statin monotherapy. Alpha-4 HDL levels were
also signiﬁcantly increased with evacetrapib com-
bined with statins.
CORRELATION ANALYSES. Correlations between
total, non–ABCA1-speciﬁc, or ABCA1-speciﬁc choles-
terol efﬂux and lipid variables at baseline are shown
in Table 1. ApoA-I, apoB, apoE, HDL-C, alpha-1, and
pre–beta-1 HDL levels were directly correlated with
total cholesterol efﬂux at baseline. Relatively high
(>0.5) correlation coefﬁcients were observed for cor-
relations between non–ABCA1-speciﬁc cholesterol
efﬂux and apoA-I, HDL-C, or alpha-1 HDL levels, and
between ABCA1-speciﬁc efﬂux and pre–beta-1 HDL
levels. At baseline, high-sensitivity C-reactive protein
and CETP activity inversely correlated with total,
ABCA1-, and non–ABCA1-speciﬁc efﬂux. No correla-
tion was observed between CETP mass and choles-
terol efﬂux.
ApoA-I, HDL-C, alpha-1, and pre–beta-1 HDL levels
were also signiﬁcantly correlated with total choles-
terol efﬂux after 12 weeks of treatment, and were
found in both pooled treatment groups (evacetrapib
monotherapy and evacetrapib plus statins) (Table 2).
Direct correlations between non–ABCA1-speciﬁc
cholesterol efﬂux and apoA-I, HDL-C, or alpha-1
HDL levels, and between ABCA1-speciﬁc efﬂux and
pre–beta-1 HDL levels were maintained on treatment,
and were present in both pooled evacetrapib treat-
ment groups. Non–ABCA1-speciﬁc efﬂux was corre-
lated directly with on-treatment CETP mass and
inversely with on-treatment CETP activity in the 2
pooled treatment groups. On-treatment CETP mass
or activity was not correlated with ABCA1-speciﬁc
efﬂux. On-treatment CETP activity and apoB con-
centrations were inversely correlated with non–
ABCA1-speciﬁc efﬂux in the pooled evacetrapib plus
statins group.
Correlations between percent changes from base-
line in total, non–ABCA1-speciﬁc, or ABCA1-speciﬁc
FIGURE 1 Percent Change in Pre–Beta-1 HDL as Measured by Immunoﬁxation and 2DGE
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Percent change in pre–beta-1 high-density lipoprotein (HDL) as measured by (A) immunoﬁxation (sample sizes: placebo, n ¼ 35; evacetrapib
30 mg, n ¼ 35; evacetrapib 100 mg, n ¼ 35; evacetrapib 500 mg, n ¼ 34; pooled evacetrapib monotherapy, n ¼ 104; atorvastatinþplacebo,
n ¼ 35; rosuvastatinþplacebo, n ¼ 34; simvastatinþplacebo, n ¼ 35; pooled statins, n ¼ 104; atorvastatinþevacetrapib, n ¼ 32; rosuvastatinþ
evacetrapib, n ¼ 31; simvastatinþevacetrapib, n ¼ 35; pooled statinsþevacetrapib, n ¼ 98) and (B) nondenaturing 2-D gel electrophoresis
(2DGE) (sample sizes: placebo, n¼ 20; evacetrapib 30mg, n¼ 20; evacetrapib 100mg, n¼ 20; evacetrapib 500mg, n¼ 20; pooled evacetrapib
monotherapy, n ¼ 60; atorvastatinþplacebo, n ¼ 20; rosuvastatinþplacebo, n ¼ 20; simvastatinþplacebo, n ¼ 20; pooled statins, n ¼ 60;
atorvastatinþevacetrapib, n ¼ 20; rosuvastatinþevacetrapib, n ¼ 20; simvastatinþevacetrapib, n ¼ 19; pooled statinsþevacetrapib, n ¼ 59).
As shown, evacetrapib monotherapy or in combination with statin increased pre–beta-1 HDL levels assessed either by immunoﬁxation or 2DGE.
Results are presented as least-square mean  SE. *p < 0.05; **p < 0.001 (vs. placebo); #p < 0.05; ##p < 0.001 (vs. statin counterpart).
Atorva ¼ atorvastatin; Rosuva ¼ rosuvastatin; Simva ¼ simvastatin.
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2206efﬂux and changes in lipid variables at week 12 are
shown in Table 2. Changes in CETP mass, HDL-C, and
apoA-I were directly correlated, whereas the change
in CETP activity and apoB were inversely correlated
with changes in total and non–ABCA1-speciﬁc efﬂux
in the 2 pooled evacetrapib treatment groups. Change
in CETP mass was also directly correlated with
changes in ABCA1-speciﬁc efﬂux in the 2 groups.
Changes in pre–beta-1 HDL were directly correlatedwith total, non–ABCA1-, and ABCA1-speciﬁc efﬂux in
the evacetrapib plus statin group, but were not
correlated with the evacetrapib monotherapy group.
DISCUSSION
This study represents the largest and most systematic
evaluation of the effects of a CETP inhibitor on
HDL CEC and on the related measure of pre–beta-1
FIGURE 2 Percent Change in Alpha-1, -2, -3, and -4 HDL Subclasses by 2DGE
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2207HDL as assessed by 2 independent methods. We
investigated the potent CETP inhibitor evacetrapib as
monotherapy or in combination with 3 different sta-
tins on these HDL-related parameters, and found that
evacetrapib, both as monotherapy and combined with
statins, signiﬁcantly increased total CEC, non–ABCA1-
speciﬁc CEC, ABCA1-speciﬁc CEC, and pre–beta-1 HDL
(Central Illustration). These robust ﬁndings demon-
strate that evacetrapib has effects on HDL function
beyond its effect in raising plasma HDL-C levels.
The efﬂux of macrophage cholesterol to HDL-
related acceptors may be a mechanism that is athe-
roprotective (16). ABCA1 transports cholesterol to
lipid-poor apoA-I particles, which are often described
as pre–beta-1 HDL, whereas ABCG1 and scavenger
receptor class B, type I (SR-BI) (which account for
most of non–ABCA1-speciﬁc efﬂux) transport choles-
terol to larger cholesteryl ester–containing HDL par-
ticles. Together, these pathways are responsible for
the bulk of macrophage total cholesterol efﬂux to
HDL (23,24), especially when macrophages are loaded
with cholesterol. Assays that measure the CEC of
HDL (using serum after depletion of apoB-containing
lipoproteins) in individuals have been evaluated
with regard to their relationship to ASCVD. Cross-
sectionally, CEC is strongly and inversely associated
with prevalent carotid intimal-medial thickness (11),
angiographic coronary artery disease (11), and preva-
lent clinical coronary artery disease (12) after adjust-
ing for HDL-C levels. Prospectively, CEC is strongly
and inversely associated with incident cardiovas-
cular events after adjusting for HDL-C levels (13,25).These results have raised the question of whether
interventions that increase CEC might favorably
affect reduction of cardiovascular events. One novel
ﬁnding of this study was the relationship between
CETP activity (or mass) and efﬂux measures at base-
line and after evacetrapib treatment. CETP activity
was inversely correlated with all efﬂux measures at
baseline, whereas on-treatment CETP activity was
inversely correlated with non–ABCA1- speciﬁc (and
total) efﬂux, but not with ABCA1-speciﬁc efﬂux.
Conversely, CETPmass had no relationship with efﬂux
measures at baseline, whereas on-treatment CETP
mass was directly correlated with almost all efﬂux
measures (especially non–ABCA1-speciﬁc efﬂux).
These ﬁndings indicate that CETP activity, in a given
individual, may inﬂuence CEC and generation of pre–
beta-1 HDL. These data support the ﬁndings from
Mendelian randomization studies that linked common
CETP variants associated with low CETP activity to
lower cardiovascular risk (7). Association of some
variants and CETP activity with CEC and pre–beta-1
HDL concentrations have been described (26).
STUDY LIMITATIONS. One potential limitation in the
current assessment of CEC is that macrophages used
in ex vivo assays are exposed to different conditions
than patients’ macrophages in vivo and are not pre-
exposed to the study drug. However, the results ob-
tained with statin monotherapy in this study suggest
that the test macrophages behaved as expected,
because decreased intracellular cholesterol and oxy-
sterol concentrations induced by statins are known
to lead to increased transcription of micro-RNA33
TABLE 2 Pearson’s Correlation Coefﬁcients (r) for Correlations Between on Treatment
or Percent Change in Total, Non–ABCA1-Speciﬁc, or ABCA1-Speciﬁc Cholesterol Efﬂux
Capacity and on Treatment or Percent Change in Lipid Variables in the Pooled Evacetrapib
Monotherapy (n ¼ 111) and Pooled Statins Plus Evacetrapib (n ¼ 114) Groups
On Treatment Percent Change
Pooled
Evacetrapib
Monotherapy
Pooled
Statins þ
Evacetrapib
Pooled
Evacetrapib
Monotherapy
Pooled
Statins þ
Evacetrapib
Total
CETP mass 0.12 0.26* 0.35† 0.54†
CETP activity –0.34† –0.11 –0.34† –0.27*
ApoB 0.01 –0.05 –0.19 –0.25*
HDL-C 0.50† 0.61† 0.39† 0.56†
ApoA-I 0.49† 0.69† 0.41† 0.57†
Pre–beta-1‡ 0.46† 0.51† 0.05 0.42†
Alpha-1§ 0.38* 0.51† 0.28 0.17
Non–ABCA1-speciﬁc
CETP mass 0.28* 0.43† 0.36† 0.42†
CETP activity –0.34† –0.35† –0.32† –0.41†
ApoB –0.05 –0.27* –0.13 –0.33†
HDL-C 0.71† 0.87† 0.29* 0.41†
ApoA-I 0.69† 0.88† 0.33† 0.41†
Pre–beta-1‡ 0.26* 0.39† –0.07 0.31*
Alpha-1§ 0.63† 0.80† 0.34* –0.01
ABCA1-speciﬁc
CETP mass –0.05 0.07 0.28* 0.25*
CETP activity –0.22 0.10 –0.15 –0.00
ApoB 0.06 0.13 –0.05 0.11
HDL-C 0.14 0.23 0.18 0.22
ApoA-I 0.15 0.34† 0.26† 0.22
Pre–beta-1‡ 0.46† 0.47† 0.14 0.34†
Alpha-1§ 0.07 0.12 0.08 –0.04
*p < 0.01. †p < 0.001. ‡Pre–beta-1 correlations are for the immunoﬁxation measurements. §Number for lipid
variables measured by 2DGE: pooled evacetrapib monotherapy (n ¼ 60) and pooled statin plus evacetrapib
(n ¼ 59).
Abbreviations as in Table 1.
TABLE 1 Pearson’s Correlation Coefﬁcients (r) for Correlations Between Baseline Total,
Non–ABCA1-Speciﬁc, or ABCA1-Speciﬁc Cholesterol Efﬂux Capacity and Lipid Variables in
All Participants (n ¼ 377)
Total Non–ABCA1-Speciﬁc ABCA1-Speciﬁc
CETP mass –0.03 0.09 –0.11
CETP activity –0.29* –0.19* –0.27*
hsCRP –0.18* –0.14† –0.15†
HDL-C 0.45* 0.61* 0.19*
ApoA-I 0.53* 0.61* 0.31*
ApoB 0.24* 0.03 0.34*
ApoE 0.31* 0.17* 0.33*
Pre–beta-1 (IF) 0.46* 0.22* 0.52*
Pre–beta-1 (2DGE)‡ 0.46* 0.22† 0.52*
Alpha-1‡ 0.38* 0.57* 0.11
*p < .001. †p < 0.01. ‡For lipid variables measured by 2DGE, n ¼ 199.
2DGE ¼ 2-dimensional gel electrophoresis; ABCA1 ¼ adenosine triphosphate–binding cassette transporter A1;
ApoA-I ¼ apolipoprotein AI; ApoB ¼ apolipoprotein B; ApoE ¼ apolipoprotein E; CETP ¼ cholesteryl ester
transfer protein; IF ¼ immunoﬁxation; HDL-C ¼ high-density lipoprotein cholesterol; hsCRP ¼ high-sensitivity C-
reactive protein.
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respectively. This results in down-regulation of the
expression of ABCA1 and ABCG1 (27). Whether evac-
etrapib affects the expression of ABCA1 and ABCG1 in
human macrophages in vivo is unknown.
CETP inhibition has been well-established to in-
crease plasma HDL-C levels, but its effect on HDL
function, as assessed by CEC, has been uncertain.
Torcetrapib monotherapy resulted in increased total
CEC at the 60 mg/day dose used in the cardiovascular
outcomes study ILLUMINATE (Investigation of Lipid
Level management to Understand its iMpact IN
ATherosclerotic Events) (9) and at the 120mg/day dose
(28) in proportion to the magnitude of HDL-C increase
with these 2 doses. The better cholesterol efﬂux with
the higher dose of torcetrapib is consistent with the
observation that subjects with greater HDL-C and
apoA-I increases on torcetrapib showed more pro-
nounced regression of coronary atherosclerosis and
appeared to have better cardiovascular outcomes (29).
Anacetrapib monotherapy, at a dose 3-fold higher than
that being studied in the cardiovascular outcomes
study REVEAL (Randomized Evaluation of the Effects
of Anacetrapib Through Lipid Modiﬁcation), also
increased total CEC (30). However, differences in
assay methodology make it difﬁcult to compare data,
because the torcetrapib and anacetrapib studies used
isolated HDL, whereas a supernatant of apoB-depleted
serum was used in the present study. Finally, dalce-
trapib 600 mg/day in combination with a statin also
minimally increased total CEC (31), in proportion with
a relatively small HDL-C increase, which was consis-
tent with the no effects on cardiovascular outcomes in
the dal-OUTCOMES (Effects of the Cholesterol Ester
Transfer Protein Inhibitor Dalcetrapib in Patients with
Recent Acute Coronary Syndrome) study (6). In that
study, Ray et al. (31) used the same methodology to
evaluate CEC that was used in the present study, but
they were not able to show any effect of dalcetrapib
treatment on ABCA1-speciﬁc CEC. Thus, the modest
increase in total CEC with torcetrapib, anacetrapib,
and dalcetrapib was largely due to non–ABCA1-speciﬁc
efﬂux, with ABCG1 playing a major role in mediating
the efﬂux potential. No previous studies have rigor-
ously assessed the impact of CETP inhibition on
ABCA1-speciﬁc efﬂux or on pre–beta-1 HDL, which is
the major acceptor of ABCA1-mediated efﬂux.
In this comprehensive study of evacetrapib, the
most unique ﬁnding was a substantial, consistent in-
crease in ABCA1-speciﬁc efﬂux, both in monotherapy
and in combination with a statin. This was accompa-
nied by signiﬁcant increases in pre–beta-1 HDL levels
as measured by 2 independent assays. The correla-
tions between pre–beta-1 HDL concentrations and
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: HDL particles
promote cholesterol efﬂux from macrophages, and CEC is
inversely associated with prevalent cardiovascular disease and
incident cardiovascular events, independently of blood levels of
HDL-C. ABCA1 plays a crucial role in cholesterol efﬂux from
macrophages, and lipid-poor pre–beta-1 HDL particles are the
rate-limiting acceptors of cholesterol via this pathway. A 12-
week course of treatment with evacetrapib, either alone or in
combination with statin therapy, increases ABCA1-speciﬁc
cholesterol efﬂux and pre–beta-1 HDL levels.
TRANSLATIONAL OUTLOOK: Further study is needed to
determine whether the increase in CEC brought about by treat-
ment with evacetrapib can reduce cardiovascular risk.
J A C C V O L . 6 6 , N O . 2 0 , 2 0 1 5 Nicholls et al.
N O V E M B E R 1 7 / 2 4 , 2 0 1 5 : 2 2 0 1 – 1 0 Evacetrapib Increases Cholesterol Efﬂux
2209ABCA1-speciﬁc efﬂux at baseline and on treatment
suggest a potential role for pre–beta-1 HDL concen-
trations as a surrogatemarker of ABCA1-speciﬁc efﬂux.
These data also imply that ABCA1-speciﬁc efﬂux
capacity was maintained on a per particle basis under
evacetrapib treatment, because ABCA-1 speciﬁc efﬂux
and pre–beta-1 HDL concentrations increased propor-
tionately. CETP inhibition is known to increase the
average size and cholesteryl ester content of HDL
particles and would not necessarily be expected to
increase the concentrations of ABCA1-driven, lipid-
poor pre–beta-1 HDL particles. However, our results
clearly establish that evacetrapib did have this effect.
Themechanisms of this effect remain unclear, but may
be related to the poorly understood processes that
generate lipid-poor, apoA-I–containingpre–beta-1HDL
particles. It is generally accepted that HDL remodeling
processes can result in desorption of apoA-I from
the surface of HDL particles, which generates lipid-
poor apoA-I. It is possible that potent CETP inhibition
makes HDL particles better substrates for certain
types of remodeling activities, such as those carriedout
by phospholipid transfer protein, endothelial lipase,
hepatic lipase, or SR-BI, which generate lipid-poor
pre–beta-1 HDL particles. The mechanisms by which
potent CETP inhibition increase ABCA1-mediated
CEC and pre–beta-1 HDL require further study.
Because our study involved statin monotherapy
arms for comparison with evacetrapib in combination
with statins, we had the opportunity to perform the
largest systematic analysis of the effects of different
statins on CEC to date. Previous studies (27,32) were
small, were generally limited to 1 statin, and used
methods to assess CEC that were less well-established.
The recent report by Niesor et al. (27) showed that
statins increased micro-R33 expression and decreased
ABCA1 expression and cholesterol efﬂux from pe-
ripheral tissues; there was a differential effect of
relatively hydrophobic statins compared with more
hydrophilic statins on the degree of cholesterol efﬂux
reduction. The present study adds incremental infor-
mation with regard to the effect of different statins on
ABCA1 cholesterol efﬂux, because both rosuvastatin
and simvastatin signiﬁcantly reduced total CEC, non–
ABCA1-speciﬁc efﬂux, and ABCA1-speciﬁc efﬂux,
whereas atorvastatin had no signiﬁcant effect on CEC.
This is interesting in light of the previous observations
that atorvastatin had less effect in raising HDL-C levels
compared with rosuvastatin and simvastatin (33). The
mechanisms by which statins reduce CEC are not un-
derstood. Even more interesting, the effect of evace-
trapib, when given in combination with a statin,
on CEC and pre–beta-1 HDL appears to be slightly
reduced with respect to evacetrapib monotherapy,although the correlation between changes in total and
ABCA1-speciﬁc CEC and pre–beta-1 HDL levels
remained robust. The mechanisms underlying the
effects of potent CETP inhibition combined with statin
therapy on CEC and pre–beta-1 HDL will need to be
elucidated in future studies.
CONCLUSIONS
Potent CETP inhibition with evacetrapib unexpectedly
increased not only total CEC but also ABCA1-speciﬁc
CEC and pre–beta-1 HDL in a dose-dependent
fashion. Furthermore, this effect was slightly reduced
by co-administration with statins, which proved to
decrease CEC asmonotherapy. These results reveal the
complex effects of potent CETP inhibition on HDL
remodeling and function that require more investiga-
tion. They also raise the possibility, in light of recent
prospective data that inversely linked CEC to incident
cardiovascular events, that this increase in CEC might
have the potential to reduce cardiovascular risk.
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